HONG KONG and NEW YORK, June 30, 2026 /PRNewswire/ — METiS TechBio (7666.HK), a leading AI-driven drug delivery innovation company, … Continue reading METiS TechBio and Boulevard Bio Enter Global License Agreement for Trispecific T-cell Engager